Hypera SA (HYPMY) recently announced a dividend of $0.06 per share, payable on a date yet to be confirmed, with the ex-dividend date set for October 5, 2023. As investors eagerly anticipate this ...

SAO PAULO, March 21 (Reuters) - Brazilian drugmaker Hypera (HYPE3.SA), opens new tab plans to launch next year a generic version of semaglutide, the active ingredient of Novo Nordisk's (NOVOb.CO), ...

SAO PAULO, Oct 24 (Reuters) - The board of directors of Brazil's pharmaceutical company Hypera (HYPE3.SA), opens new tab has unanimously decided to reject rival EMS's offer to merge, it said on ...

Hypera SA (HYPMY) recently announced a dividend of $0.02 per share, payable on a date yet to be confirmed, with the ex-dividend date set for 2024-03-22. As investors look forward to this upcoming ...

Brazilian pharmaceutical company Hypera has discussed a takeover offer from rival company NC Group, the owner of EMS SA, but talks are not currently active, one source with knowledge of the matter ...

Hypera SA (HYPMY) recently announced a dividend of $0.02 per share, payable on a date yet to be confirmed, with the ex-dividend date set for 2024-03-22. As investors look forward to this upcoming ...

Brazil's leading pharmaceutical company Hypera SA believes it can sustain market share gains it had this year and deliver on guidance for 2022, CEO Breno Oliveira told analysts in a conference call on ...

Hypera SA is a pharmaceutical company, which engages in the manufacture and distribution of medical and cosmetics products. It operates through the following segments: Prescription Products, Consumer ...

Hypera Pharma, along with all Rimini Street clients, benefits from the Company’s flexible, premium-level enterprise software support model, including its industry-leading Service Level Agreement (SLA) ...

Brazilian pharmaceutical company Hypera said on Thursday it expects 1.7 billion reais ($331.83 million) in net income for 2022. The company also said it sees its 2022 adjusted earnings before interest ...